Kestra Medical Technologies (NASDAQ:KMTS) Now Covered by Oppenheimer

Oppenheimer initiated coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research report sent to investors on Tuesday, Marketbeat.com reports. The firm issued a market perform rating on the stock.

Several other research analysts have also weighed in on the company. BTIG Research increased their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. The Goldman Sachs Group cut their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Finally, Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $27.83.

Kestra Medical Technologies Stock Performance

Shares of KMTS stock opened at $22.24 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -9.19 and a beta of 0.47. Kestra Medical Technologies has a one year low of $14.10 and a one year high of $30.00. The company has a 50 day moving average price of $22.32 and a 200 day moving average price of $22.63.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million during the quarter. Sell-side analysts anticipate that Kestra Medical Technologies will post -2.3 EPS for the current year.

Insider Activity at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total value of $312,150.00. Following the transaction, the insider owned 395,467 shares of the company’s stock, valued at approximately $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its stake in shares of Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares during the period. Quantinno Capital Management LP acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at about $431,000. Sei Investments Co. raised its holdings in shares of Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares during the period. Finally, Spartan Wealth Advisory Services LLC purchased a new stake in shares of Kestra Medical Technologies during the 1st quarter valued at about $603,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.